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Nosocomial infections are a common occurrence in patients following traumatic brain 
injury (TBI) and are associated with an increased risk of mortality, longer length of hospital 
stay, and poor neurological outcome. Systemic immune suppression arising as a direct 
result of injury to the central nervous system (CNS) is considered to be primarily respon-
sible for this increased incidence of infection, a view strengthened by recent studies that 
have reported novel changes in the composition and function of the innate and adaptive 
arms of the immune system post-TBI. However, our knowledge of the mechanisms that 
underlie TBI-induced immune suppression is equivocal at best. Here, after summarizing 
our current understanding of the impact of TBI on peripheral immunity and discussing 
CNS-mediated regulation of immune function, we propose roles for a series of novel 
mechanisms in driving the immune suppression that is observed post-TBI. These mech-
anisms, which have never been considered before in the context of TBI-induced immune 
paresis, include the CNS-driven emergence into the circulation of myeloid-derived sup-
pressor cells and suppressive neutrophil subsets, and the release from injured tissue of 
nuclear and mitochondria-derived damage associated molecular patterns. Moreover, 
in an effort to further our understanding of the mechanisms that underlie TBI-induced 
changes in immunity, we pose throughout the review a series of questions, which if 
answered would address a number of key issues, such as establishing whether manipu-
lating peripheral immune function has potential as a future therapeutic strategy by which 
to treat and/or prevent infections in the hospitalized TBI patient.
Keywords: traumatic brain injury, immune system, immune suppression, infection
iNTRODUCTiON
Defined as “an alteration in brain function, or other evidence of brain pathology, caused by an 
external force” (1), traumatic brain injury (TBI) represents a major public health issue and socio-
economic problem worldwide. An injury with multiple underlying etiologies, which include road 
traffic collisions, assaults, and falls, TBI was the primary diagnosis in 177,239 hospital admissions 
in England in 2013–2014 (2), while in the United States, an estimated 1.7 million people sustain a 
TBI annually, culminating in ~1.4 million emergency department visits, 275,000 hospitalizations 
and 52,000 fatalities (3).
The clinical impact of TBI is highlighted not only by its high mortality rate [TBI contributes to 
a third of all injury-related deaths in the United States (3)] but by the significant long-term health 
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complications reported by those who survive their injuries. 
Personality changes, anxiety, depression, short attention span, 
difficulty in information processing, as well as impaired co-
ordination and balance are commonly reported by patients with 
non-fatal TBI, all of which pose significant challenges to their 
independent living, social reintegration, and working life (4, 5). 
Moreover, in addition to the physiological and psychological 
impact on the individual and their families, the effects of TBI 
extend to society as a whole. Across Europe in 2010, the economic 
cost of TBI was an estimated €33 billion (6), while in the United 
States, where around 5.3 million people are living with a TBI-
related disability (7), the economic cost of TBI exceeds $70 billion 
per year (8).
Hospital-acquired infections (HAIs) are a frequent occurrence 
in patients with severe TBI. As a result of colonization by such 
organisms as Staphylococcus aureus (S. aureus), Pseudomonas 
aeruginosa, and Haemophilus influenza, lower respiratory tract 
and surgical site infections are two of the most common non-neu-
rological complications following severe TBI with an incidence 
rate of 24–72 and 17–25%, respectively (9–14). While it is cur-
rently unclear whether HAIs in TBI patients are associated with 
an increased risk of death (11, 15–19), numerous studies have 
demonstrated that HAIs result in significant patient morbidity. 
For instance, when compared to their non-infected counterparts, 
TBI patients with HAIs have significantly longer intensive care 
unit and hospital lengths of stay (11, 15, 17, 20), a greater degree 
of organ system dysfunction (11, 15), an increased duration of 
mechanical ventilation (11, 15, 20), and a worse neurological 
outcome at follow-up (14, 21). This detrimental effect of infection 
on neurological recovery has also been demonstrated in rodent 
trauma models, where in mild TBI, Venturi et al. (22) showed that 
the superimposition of sepsis resulted in a significant exacerba-
tion of postinjury motor deficit and cognitive impairment as well 
as increased neuronal cell death in the hippocampus (22).
Multiple risk factors have been shown to be independently 
associated with the development of infections in hospitalized TBI 
patients. These include nasal carriage of S. aureus and barbiturate 
use (10), prolonged hospitalization, surgical intervention and cer-
ebrospinal fluid leak (13), damage to the central nervous system 
(CNS), and the need for intubation and mechanical ventilation 
(12). Of these, it is injury to the CNS that is considered the main 
factor driving the increased susceptibility of TBI patients to HAIs. 
Mechanistically, this has been attributed to CNS injury disrupt-
ing the well-balanced bidirectional communication that exists 
between the CNS and the immune system, resulting in a state of 
systemic immune suppression (23). Indeed, in vitro and in vivo 
studies have shown significant changes occur in the number, 
phenotype, and function of cells belonging to both the innate and 
adaptive arms of the immune system post-TBI, a phenomenon 
termed CNS injury-induced immune deficiency syndrome (23).
In this article, we provide a comprehensive overview of the 
impact that TBI has on the circulating peripheral immune sys-
tem and propose that alongside the well-described CNS-driven 
mechanisms of immune suppression, a series of novel immune-
mediated mechanisms contribute to the altered immune function 
observed postbrain injury. Moreover, we highlight key areas of 
research that need to be tackled by future studies if we are to 
gain a greater understanding of the mechanisms underlying TBI-
induced changes in immunity and establish whether manipula-
tion of the immune system could become a potential therapeutic 
avenue by which to treat the hospitalized TBI patient.
CURReNT UNDeRSTANDiNG OF THe 
iMPACT OF TBi ON THe PeRiPHeRAL 
iMMUNe SYSTeM
Via a combination of historical observations (24–30) and 
results derived from recent experimental studies (31–38), it is 
evident that TBI has a significant impact on both the function 
and composition of the circulating immune cell pool. In this 
section, we provide a detailed description of the changes that 
have been reported to occur in both the innate and adaptive 
arms of the peripheral immune system following TBI, focusing 
predominantly on results obtained from human-based studies 
(Table 1). Given that very few of these studies have provided a 
mechanistic explanation for the changes they report, we make 
reference, where appropriate, to studies conducted in other fields 
of research whose results we believe offer plausible explanations 
for some aspects of immune dysfunction that have been reported 
post-TBI.
innate immunity
Neutrophils
Armed with an array of microbicidal mechanisms, which include 
reactive oxygen species (ROS) generation and phagocytosis, neu-
trophils are the most abundant leukocyte in human circulation 
and the first immune cell to arrive at a site of pathogenic chal-
lenge. Following TBI, leukocytosis occurs, the result of profound 
neutrophilia. Both in the immediate aftermath of TBI as well as 
in the days following injury, studies have shown that relative to 
healthy control values, both the absolute number (34, 35, 39) and 
frequency (34, 39) of circulating neutrophils are significantly 
increased, with one study reporting a 4.5-fold elevation in neu-
trophil numbers as early as 3 h post-TBI (39). This immediate 
neutrophilia is thought to result from TBI-induced increases in 
serum catecholamines and glucocorticoids (33). A surge in cat-
echolamines would trigger the entry of marginated neutrophils 
into the circulation, while a rise in glucocorticoid levels would 
increase the size of the peripheral neutrophil pool by stimulating 
their release from bone marrow stores and by extending their 
lifespan and preventing circulating neutrophils from return-
ing to the bone marrow for clearance (33, 42). In terms of the 
neutrophilia that has been observed up to 48 h postinjury (39), 
Junger et al. (34) recently reported significantly fewer neutrophils 
isolated from TBI patients undergo spontaneous apoptosis dur-
ing an overnight culture in vitro when compared to those from 
uninjured controls (34). Thus, a TBI-induced extension in neu-
trophil life-span may explain the elevated number of circulating 
neutrophils that have been reported in the days following injury.
In the immediate hours and days following mild, moderate, or 
severe TBI, neutrophils exhibit increased ROS generation, both in 
their resting state (35) as well as in response to stimulation with 
the bacterial peptide formyl-methionine-leucine-phenylalanine 
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(fMLP) and the protein kinase C activator phorbol 12-myristate 
13-acetate (PMA) (34). In a recent study, Liao et  al. attributed 
the enhancement in basal ROS generation to a TBI-induced 
increase in gp91phox (35). The heme binding subunit of the ROS 
generating enzyme nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (43), Liao et al. found gp91phox expression was 
significantly higher in leukocytes isolated from TBI patients within 
24 h of their injury when compared to leukocytes from uninjured 
controls (35). Interestingly, besides healthy controls, neutrophils 
from TBI patients generated significantly more ROS at rest and 
expressed higher amounts of gp91phox than neutrophils obtained 
from patients that had suffered general trauma with no CNS injury 
(35), suggesting that TBI initiates a more robust oxidative response 
than non-head trauma. While the mechanism(s) underlying this 
exaggerated response are currently unknown, the loss of regulatory 
feedback control on immune function as a result of direct CNS 
injury has been proposed as one potential explanation (35).
In contrast to the enhanced ROS generation that characterizes 
the initial response to TBI (34, 35), neutrophils exhibit impaired 
ROS generation in the days following injury (36, 40). In a study of 
hospitalized TBI patients with moderate or severe brain trauma, 
Marks et al. (36) found that neutrophil ROS production on day 
9 postinjury was significantly lower than that of healthy age- and 
sex-matched controls. Given that peak incidences of infection 
in hospitalized TBI patients occur 5–11  days after injury (21, 
36), and neutrophils are the first line of defense against rapidly 
dividing bacteria, fungi, and yeast; then impaired ROS generation 
may be one mechanism underlying the increased susceptibility of 
hospitalized TBI patients to infection. With this in mind, a com-
parison of ROS generation between neutrophils isolated from 
non-infected and infected TBI patients revealed a significantly 
greater percentage of ROS producing cells in the uninfected 
group on day 6 postinjury (36).
TABLe 1 | Summary of TBi-induced changes in peripheral innate and adaptive immunity.
Frequency/absolute numbers Function Reference
Neutrophils Increased frequency and absolute number Increased basal ROS generation (39)
Enhanced fMLP and PMA-induced ROS production in the acute  
phase of TBI
(34)
Impaired ROS generation to E. coli stimulation at day 9 postinjury (35)
Reduced phagocytosis (36)
Monocytes Increased absolute number of total 
monocytes
Increased intracellular IL-10 expression (30)
(39)
Increased absolute number of anti-
inflammatory “M2” monocytes
(35)
(37)
Natural killer  
cells
Decreased frequency and absolute number  
of CD3−56+ NK cells
Increased percentage of perforin-positive CD3−56+, CD56DIM and 
CD56BRIGHT NK cells at day 1 postinjury
(40)
Decreased frequency of CD56DIM NK cells Decreased percentage of perforin-positive CD3−56+ and  
CD56DIM NK cells at day 4 postinjury
(41)
No change in CD56BRIGHT NK cell frequency (31)
(32)
(38)
T cells Decreased percentage and absolute  
number of CD3+, CD4+, and CD8+ T cells
Decreased proliferation and cytokine production in response to  
PHA stimulation
(25, 27–29)
(40)
Reduced LAK cytotoxicity (41)
Impaired DTH response (31)
DTH, delayed-type hypersensitivity; E. coli, Escherichia coli; fMLP, formyl-methionine-leucine-phenylalanine; IL, interleukin; LAK, lymphokine-activated killer; PHA, phytohemagglutinin; 
PMA, phorbol 12-myristate 13-acetate; ROS, reactive oxygen species; TBI, traumatic brain injury.
Following TBI, the ability of circulating neutrophils to phago-
cytose immunoglobulin and complement-coated Escherichia coli 
(E. coli) is significantly reduced (35, 36). This impairment, which 
has been observed in the hours (35), days (35, 36), and weeks (35) 
following injury relates to both the percentage of phagocytosing 
cells as well as their individual cellular activity (number of E. coli 
engulfed per cell). The reduction in phagocytosis that occurs 
post-TBI is significantly greater than that which occurs following 
general trauma with no CNS injury (35) and has been suggested 
to reflect a compensatory mechanism aimed at minimizing the 
deleterious effects of the afore-mentioned TBI-induced increase 
in neutrophil ROS generation (35). In the setting of critical ill-
ness, a reduction in neutrophil phagocytosis akin to that observed 
following TBI has been reported in patients with suspected ven-
tilator-associated pneumonia (44), an impairment that has been 
attributed to activation of the complement system (44, 45). More 
specifically, it has been shown that by activating the delta isoform 
of phosphoinositide 3-kinase, the complement component C5a 
inhibits the Rho GTPase RhoA, which is the key mediator of the 
actin polymerization that is required for neutrophils to engulf 
complement-coated pathogens (45, 46). While it is currently 
unknown as to whether in  vivo exposure to C5a mediates the 
reduced uptake of complement-coated E. coli by neutrophils 
post-TBI, this is a mechanism worth investigating given that 
complement activation is a feature of the inflammatory response 
to TBI (47, 48) and in a murine model of TBI, C5a was found to 
influence the functional behavior of circulating neutrophils (49).
Monocytes
Monocytes are a heterogeneous population of blood-borne 
leukocytes that comprise ~5–10% of the circulating immune cell 
pool and based on the differential surface expression of CD14 and 
the Fc receptor CD16 are categorized into one of three distinct 
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subsets: classical (CD14++16–), non-classical (CD14+16++), or 
intermediate (CD14++16+) (50). Currently, there is a paucity of 
information on what effect TBI has on monocyte biology, with a 
small number of groups focusing upon changes in their number, 
surface phenotype, and cytokine production.
In contrast to murine-based studies, where significant reduc-
tions in monocyte number have been observed in the early 
hours and days following TBI (37), human studies have shown 
that TBI leads to a significant elevation in the absolute number 
of circulating monocytes (35, 39). Whether this increase in 
monocytes, whose numbers in one study were 2.7-fold higher 
relative to healthy controls within 24  h of injury (35), is the 
result of an increase in all monocytes or reflects the expansion of 
specific subsets which is currently unknown. However, changes 
that have been described in the surface phenotype of circulating 
monocytes post-TBI suggest that the latter is responsible. The 
selectin CD62L, which mediates initial tethering and rolling of 
marginated cells along the vessel wall, is expressed exclusively 
on CD14++16– classical monocytes (51, 52), while the β2-integrin 
CD11b is present in greater amounts on the surface of both clas-
sical and intermediate monocyte subsets than on non-classical 
monocytes (52). Following TBI, analysis of the monocyte pool 
in its entirety has revealed significant increases in CD11b and 
CD62L surface density (39). Given the expression profiles of these 
two adhesion markers, this data suggests that it is expansion of 
both the classical and intermediate subsets that drives the signifi-
cant elevation in monocyte number observed post-TBI (35, 39).
In addition to surface phenotype, monocytes can be catego-
rized into distinct subsets based upon their inflammatory proper-
ties and maturation profiles. In mice, Ly6C+ classical monocytes 
secrete proinflammatory cytokines and following entry into 
tissue mature into inflammatory M1 macrophages, while Ly6C– 
non-classical monocytes secrete the anti-inflammatory cytokine 
IL-10 and differentiate into anti-inflammatory M2 macrophages 
(53). In a murine model of closed head injury, Schwulst et  al. 
(37) found a significantly greater number of anti-inflammatory 
Ly6C− monocytes in the peripheral circulation of TBI mice at 
60 days postinjury when compared to sham controls, suggesting 
that TBI results in a shift toward an anti-inflammatory monocyte 
pool (37). In line with this observation, intracellular expression 
of IL-10 has been detected in monocytes isolated from human 
TBI patients immediately after injury (30), suggesting that akin 
to the situation described in mice, TBI in humans elicits an anti-
inflammatory response in circulating monocytes.
Natural Killer Cells
Phenotypically defined as CD3−56+, natural killer (NK) cells 
are large granular lymphocytes renowned for their role in the 
recognition and elimination of virally infected, malignant, and 
transformed cells. In the days (31, 38) and weeks (38) following 
mild (38), moderate (38), and severe (31, 38) TBI, significant 
reductions have been reported in the absolute number and fre-
quency of circulating NK cells. These measures correlated posi-
tively with both the Glasgow coma scale (GCS) score, suggesting 
that the changes observed could be a direct consequence of the 
brain injury (31, 38), and the Glasgow outcome scale (GOS), 
suggesting a relationship between immune status and physiologi-
cal recovery (38). Based on the differential surface expression 
of CD56, NK cells can be categorized into two major subsets, 
namely cytotoxic CD56DIM NK cells and immunoregulatory 
CD56BRIGHT NK cells. Following TBI, the frequency of CD56DIM 
but not CD56BRIGHT NK cells is significantly diminished (31), 
indicating that it is a specific reduction in the CD56DIM subset 
that is responsible for the above-mentioned decline in the total 
(CD3−56+) NK cell pool.
While it is currently unclear as to why TBI results in a 
significant decline in the number of circulating NK cells, one 
school of thought is that it represents a mechanism by which to 
prevent autoimmunity and CNS inflammation (38). In vitro, NK 
cells have been shown to kill resting microglia (54), the resident 
macrophage-like cell of the CNS that upon activation produces 
proinflammatory cytokines and acquires the ability to process and 
present antigens to CNS infiltrating T cells (55). Furthermore, it 
has been shown in vivo that CNS residing NK cells suppress the 
microglia-mediated induction of proinflammatory T helper 17 
cells (56, 57). Thus, it has been proposed that the reduction in 
circulating NK cell numbers post-TBI is the result of NK cells 
entering the brain via the damaged blood–brain barrier, where 
through influencing microglial number and function they prevent 
the amplification of inflammatory processes and thus bystander 
damage in the CNS (38). An alternative mechanism that could 
explain the decline in circulating NK cell numbers post-TBI is 
cell death. As reported for other lymphocytes, glucocorticoid 
treatment in vitro has been shown to induce apoptosis in resting 
NK cells (58, 59). Thus, it is conceivable that the increase in serum 
glucocorticoids that accompanies TBI could trigger the induction 
of programed cell death in circulating NK cells, culminating in a 
significantly reduced peripheral pool.
NK cells eliminate transformed cells primarily via the granule 
exocytosis pathway, a contact-dependent mechanism of defense 
that involves the directed secretion of the pore-forming protein 
perforin onto the target cell surface. Within 24 h of severe TBI, 
significant increases have been reported in the percentage of 
perforin-positive CD3−CD56+, CD56DIM and CD56BRIGHT NK 
cells (32). As perforin expression is enhanced by proinflam-
matory cytokines (60), this increase in perforin positive NK 
cells has been proposed to be due to the leakage of interleukin 
(IL)-1, IL-6, and tumor necrosis factor-alpha (TNF-α) from the 
CNS into the circulation (32). Interestingly, by day 4 post-TBI, a 
time-point where the frequency of perforin-positive CD3−CD56+ 
NK cells correlates positively with GCS score, the percentage of 
perforin-positive CD3−CD56+ and CD56DIM NK cells is signifi-
cantly reduced relative to healthy controls (32), a decline that may 
contribute to the increased susceptibility of the hospitalized TBI 
patient to infection.
Adaptive immunity
Until recently, TBI was thought to have no impact upon B-cell 
biology, a belief based upon a handful of studies that had shown 
no alterations in the frequency, absolute number, or prolifera-
tive capacity of B cells following severe TBI (24, 28, 31, 40, 61). 
However, in two recent studies, autoantibodies specific for CNS 
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proteins were detected in the serum of TBI patients, suggesting 
that following TBI, self-tolerance is broken and B cells initiate 
an immune response against brain-derived antigens. In the 
setting of mild TBI, Marchi et  al. found that serum levels of 
the astrocytic protein S100B were higher in subjects that had 
experienced frequent sub-concussive head hits (SHH) and that 
the presence of this protein was accompanied by an elevation in 
anti-S100B autoantibodies (62). As raised S100B autoantibody 
levels were associated with poor performance in cognitive 
tests, and these autoantibodies reacted strongly toward both 
glial and neuronal cell epitopes, it was hypothesized that the 
generation of autoantibodies against CNS-residing proteins 
may represent a risk factor for premature neurodegeneration in 
individuals who suffer repeated SHH (62). In line with these 
observations, Zhang et  al. detected autoantibodies against the 
astrocyte-residing intermediate filament protein glial fibrillary 
acidic protein (GFAP) and its breakdown products in serum 
samples obtained from 53 patients following severe TBI (63). 
These GFAP autoantibodies, which were detected as early as 
4  days postinjury and whose levels positively correlated with 
GCS scores, were shown to induce glial cell injury in vitro, sug-
gesting a potential pathophysiological role for B cells during the 
recovery phase of TBI (63).
Severe TBI results in a significant decrease in the percentage 
and absolute number of circulating T lymphocytes (31, 40, 41). 
This decrease, which has been observed within 24 h of injury 
(31, 41) as well as on day 4 postinjury (31), is the result of a 
significant reduction in both CD4+ T helper cells and CD8+ 
cytotoxic T cells (31, 40, 41). Currently, the mechanism(s) 
underlying this TBI-induced shrinkage of the circulating T-cell 
pool is unclear although results of a recent murine-based study 
offer a potential explanation. In a series of in vivo experiments, 
Nakai et  al. (64) found that administration of B2-adrenergic 
receptor (B2AR) agonists resulted in a rapid reduction in 
the numbers of blood CD4+ and CD8+ T cells, with further 
investigations revealing this lymphopenia was the result of 
B2AR stimulation inhibiting lymphocyte egress from lymph 
nodes (64). Given that TBI results in increased circulating 
levels of catecholamines (65, 66), then lymphocyte retention 
in lymph nodes may be one mechanism by which to explain 
the significant reduction in circulating T cells that has been 
observed following TBI.
Alongside numerical changes, a multitude of functional defects 
have been reported in circulating T cells following TBI. While 
in vitro studies have shown that T cells isolated from patients with 
severe TBI exhibit reduced proliferation and cytokine production 
following phytohemagglutinin stimulation (26–28) as well as 
impaired lymphokine-activated killer (LAK) cytotoxicity follow-
ing incubation with IL-2 (26, 27, 29), in vivo studies have revealed 
severe TBI results in suppressed delayed-type hypersensitivity 
(DTH) skin test responses to a range of antigens, which include 
Candida, mumps, and trichophyton (25, 28, 61). Mechanistically, 
this reduction in cell-mediated immunity has been suggested to 
be due to serum factors with immune-suppressive activity (29, 
61) and the presence of suppressor lymphocytes that actively 
inhibit effector lymphocyte function (29).
NeURAL ReGULATiON OF THe iMMUNe 
ReSPONSe
Critical for the regulation of peripheral inflammatory responses 
is the bidirectional communication that exists between the 
immune system and the CNS. The brain senses peripheral inflam-
mation via two main pathways; a neural pathway, which involves 
activation of the afferent sensory fibers of the vagus nerve, and 
a humoral pathway, in which circulating cytokines signal to the 
brain either by crossing the blood–brain barrier or by binding 
their cognate receptors on the brain microvasculature (67, 68). 
Interestingly, a functional lymphatic system within the CNS 
has recently been discovered, suggesting an additional level of 
communication between the CNS and the immune system (69, 
70). Of particular interest with regards to TBI, Louveau showed 
B cells, T cells, and dendritic cells reside in meningeal lymphatic 
vessels and that these vessels serve as the primary route for the 
drainage of cerebrospinal fluid (CSF)-derived soluble and cellular 
constituents into cervical lymph nodes (CLNs) (70). Given that 
the contents of CSF have been shown to trigger immune responses 
in CLNs (71), this CNS lymphatic system may represent a novel 
means by which the immune system could detect alterations in 
brain physiology post-TBI.
Having sensed peripheral inflammation, the brain, in an effort 
to restore immune homeostasis, responds by signaling to the 
immune system via three immunomodulatory pathways: (1) the 
hypothalamic–pituitary–adrenal (HPA) axis (2) the sympathetic 
nervous system (SNS), and (3) the parasympathetic nervous 
system (PNS). In the context of TBI and peripheral immune 
suppression, the direct injury to the brain and/or the resulting 
ischemia, raised intracranial pressure and cerebral cytokine pro-
duction that develops in the days and weeks postinjury is thought 
to disrupt the well-balanced interplay between the immune sys-
tem and the CNS. Activation of the above-mentioned pathways 
of neural immune modulation in the absence of a peripheral 
inflammatory response culminates in a state of systemic immune 
depression that is thought to increase the risk of the TBI patient 
to nosocomial infection. Here, we provide a brief overview of the 
three above-mentioned neural pathways of immune modula-
tion, highlighting key studies whose results suggest that these 
pathways may play a prominent role in mediating TBI-induced 
immune suppression.
The Hypothalamic–Pituitary–Adrenal Axis
The HPA axis represents the primary hormonal pathway 
through which the CNS regulates peripheral immune function. 
Glucocorticoids, the main effector hormone of the HPA axis, 
modulate immune cell functions via binding to the glucocorticoid 
receptor, a cytosol residing ligand-dependent transcription fac-
tor, which modulates the expression of genes involved in cytokine 
production and such immune responses as cell trafficking and 
phagocytosis (72).
Via a series of mechanisms, which range from the destabiliza-
tion of mRNA to inhibiting the binding of transcription factors 
to DNA (73), glucocorticoids suppress the production of several 
proinflammatory cytokines and inflammatory mediators, which 
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include IL-1β, IL-6, IL-12, TNF-α, IFN-γ, nitric oxide, and 
prostaglandins (74–76). In contrast, glucocorticoids promote the 
secretion of the anti-inflammatory cytokines IL-4 and IL-10 (75). 
Through this modulation of inflammatory cytokine production, 
glucocorticoids effect immune cell trafficking by suppressing 
TNF-α-mediated increases in endothelial cell surface adhesion 
molecules (77) and influence T-cell biology by driving the dif-
ferentiation of naive T lymphocytes to T helper 2 (TH2) cells and 
blocking TH1 development (78, 79).
In terms of their effects on immune cell function, gluco-
corticoids have been found to increase the T-cell-suppressive 
capacity of anti-inflammatory “M2” macrophages (80), suppress 
the cytotoxicity activity of NK cells by decreasing expression 
of the pore-forming protein perforin (81), inhibit neutrophil 
phagocytosis (82), induce lymphocyte apoptosis (83), and influ-
ence the antigen-presenting capacity of monocytes and dendritic 
cells by downregulating their expression of MHC class II and the 
costimulatory molecule CD86 (84, 85).
The Sympathetic Nervous System
Through extensive innervation of primary (bone marrow and 
thymus) and secondary (lymph nodes and spleen) lymphoid 
organs and the expression of α and β adrenergic receptors on 
the surface of almost all circulating leukocytes, the SNS elicits 
a strong regulatory influence on peripheral immune function 
(86). In a series of in  vitro experiments, catecholamines, the 
effector neurotransmitter of the SNS, or their pharmacological 
analogs have been shown to suppress, in a β-adrenergic receptor-
dependent manner, a range of immune functions, which include 
neutrophil ROS generation, inflammatory cytokine production, 
and NK-cell cytotoxicity (86–91). With respect to cytokine 
production, pretreatment of whole blood or isolated monocytes, 
macrophages, or dendritic cells with epinephrine, norepineph-
rine, or the β2-agonist salbutamol has been found to significantly 
inhibit lipopolysaccharide (LPS)-induced IL-12 and TNF-α 
secretion (88, 89, 91, 92), a suppression that in the case of IL-12 
was associated with an increase in intracellular cyclic adenosine 
monophosphate levels (92). While inhibiting proinflammatory 
cytokine production, catecholamines enhance the generation of 
anti-inflammatory cytokines, with epinephrine and norepineph-
rine treatment of whole blood or isolated monocytes significantly 
increasing both basal and LPS-induced secretion of IL-10 (88, 
89, 93). Via these effects on inflammatory cytokine production, 
β-adrenergic receptor stimulation has been shown to indirectly 
influence the differentiation of naive T cells, promoting the 
development of TH2 cells and inhibiting the generation of TH1 
cells (92). Given that TBI results in elevated circulating levels of 
catecholamines (65, 66), this catecholamine-induced shift in the 
TH1/TH2 balance in favor of anti-inflammatory TH2 cells may be 
one factor behind the increased susceptibility of TBI patients to 
infection.
In line with the in vitro effects of catecholamines, human- and 
murine-based ex vivo studies have demonstrated in a number of 
experimental settings an immune suppressive role for the SNS 
(90, 93–95), which in the case of direct CNS injury has been 
linked to the development of infection. In a murine model of 
stroke, Prass et al. found that inhibition of the SNS immediately 
following the onset of cerebral ischemia improved survival rates 
by preventing the spontaneous development of systemic bacterial 
infections that was observed in control mice (95). Underlying 
this protective effect was an enhanced immune response with ex 
vivo experiments, revealing that inhibition of the SNS prevented 
a stroke-induced reduction in IFN-γ production by circulating 
T lymphocytes; a function that the group found was crucial in 
controlling bacterial infections’ poststroke (95).
Both prospective and retrospective cohort studies have 
shown that the use of β-adrenergic receptor antagonists in 
adult TBI patients is independently associated with improved 
survival (96–98). Given that a reduced risk of ischemia, 
enhanced brain tissue metabolism and oxygen consumption as 
well as protection of the cardiovascular system are all potential 
benefits of this treatment protocol (98–101), it is likely that 
alterations to a number of physiological processes underlie this 
protective effect of β-adrenergic receptor blockade on patient 
survival post-TBI. However, could reducing the incidence of 
infection by preventing SNS-induced immune suppression be an 
additional underlying mechanism? This hypothesis has been 
rebuffed by some groups who reported a higher incidence of 
infectious complications among TBI patients treated with 
β-adrenergic receptor antagonists (97, 102). However, in these 
studies, patients who underwent this treatment protocol were 
older, more-severely injured and received a higher number of 
blood transfusions than their untreated counterparts (97, 102). 
Moreover, in one study, many of the patients did not com-
mence their therapy until after the diagnosis of infection (97). 
Thus, to answer this question correctly, a study that performs 
β-adrenergic receptor blockade in a randomized, double-
blinded, placebo-controlled trial of appropriately matched TBI 
patients that measures immune function, infection incidence, 
and outcome is required. Results of such a study would go a 
long way to addressing whether in the clinical setting of TBI, 
the surge in circulating catecholamines is causally linked to the 
subsequent development of immune suppression, and if so what 
impact this has on patient outcome.
The Parasympathetic Nervous System
In a landmark study in 2000, Borovikova et al. described for the 
first time a vagus nerve-mediated parasympathetic pathway of 
immune modulation. After showing in vitro that treating primary 
human macrophage cultures with acetylcholine (ACh), the prin-
cipal parasympathetic neurotransmitter significantly inhibited 
LPS-induced secretion of TNF-α, IL1-β, IL-6, and IL-18 without 
affecting the production of the anti-inflammatory cytokine IL-10, 
the group demonstrated in vivo a role for parasympathetic signal-
ing in regulating systemic inflammatory responses (103). In a rat 
model of lethal endotoxemia, electrical stimulation of the efferent 
vagus nerve (which increases ACh release) significantly reduced 
serum TNF-α levels, whereas in mice subjected to vagotomy 
without electrical stimulation, TNF-α levels were significantly 
increased when compared to sham-operated controls (103). 
These two novel findings were the first to directly implicate 
efferent vagus nerve signaling in the regulation of proinflam-
matory cytokine production in  vivo. Termed the cholinergic 
“anti-inflammatory” pathway, this neural mechanism of immune 
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modulation is rapid, discrete, and localized when compared to 
the diffusible anti-inflammatory network (e.g., glucocorticoids 
and anti-inflammatory cytokines), therefore allowing for “real 
time” regulation of immune responses (103, 104).
As well as exerting anti-inflammatory effects in models of 
systemic inflammation such as severe sepsis (105, 106), haemor-
rhagic shock (107), and ischemia/reperfusion (108), a role for 
parasympathetic signaling in regulating localized peripheral 
inflammatory responses has been reported. In an experimental 
model of carrageenan-induced paw edema, electrical stimulation 
of the vagal nerve or local administration of ACh significantly 
attenuated the development of acute inflammation (109), an 
outcome that may be explained by the ability of ACh to inhibit 
endothelial cell activation and leukocyte recruitment (110).
The essential signaling component that links ACh release from 
efferent vagal fibers to peripheral immune suppression is the α7 
subunit of the nicotinic ACh receptor (106, 111). In vitro treat-
ment of human macrophages with antisense oligonucleotides 
specific for the α7 subunit has been shown to restore TNF-α 
secretion upon nicotine stimulation (111), while peritoneal 
macrophages isolated from α7 subunit deficient mice were found 
to be refractory to cholinergic agonists, secreting significantly 
greater amounts of TNF-α following LPS stimulation in the 
presence of ACh or nicotine when compared to macrophages 
from control mice (111). Moreover, in vivo studies have reported 
elevated serum levels of TNF-α, IL1-β, and IL-6 in α7-subunit-
deficient mice after endotoxin challenge and shown that electrical 
stimulation of the vagus nerve in these mice fails to reduce this 
proinflammatory response (111).
Based on the results of the afore-mentioned studies and 
clinical data suggesting TBI results in enhanced parasympathetic 
activity (112), it has been hypothesized that overactivity of the 
vagus nerve may be responsible, at least in part, for the periph-
eral immune suppression that is observed following TBI (113, 
114). An increase in vagal tone would occur as either a direct 
consequence of the TBI or as a result of elevated intracranial 
pressure, leading to systemic immune suppression that increases 
the susceptibility of the hospitalized TBI patient to infection (113, 
114). Although plausible, it must be noted that no clinical stud-
ies have been performed to date that have investigated a role for 
parasympathetic signaling in mediating the increased incidence 
of infection in TBI patients. That said, if this theory is proven to 
be correct then modulating the activity of the vagus nerve could 
be a novel therapeutic approach by which to reduce not only the 
direct mortality attributable to infection but also the long-term 
effects of infection in respect to poor neurological outcome in 
TBI patients (113, 114).
New CONCePTS iN TBi-iNDUCeD 
iMMUNe SUPPReSSiON
In spite of the recent increase in the number of studies that 
have investigated the effect of TBI on peripheral immunity (31, 
32, 34–39), only one has provided a mechanistic explanation 
for their findings (35), with the majority merely reporting 
functional impairments relative to healthy controls (31, 32, 
36, 37). This paucity of information on the mechanisms that 
underlie TBI-induced changes in immunity represents a major 
barrier that needs to be overcome if novel immune-based 
therapeutic strategies aimed at reducing the incidence of 
nosocomial infection in hospitalized TBI patients are to be 
developed. While disruption of the well-balanced interplay 
that exists between the nervous system and the immune system 
clearly plays a key role in TBI-induced immune suppression 
(23), it is likely that additional mechanisms are involved. In 
other forms of traumatic injury, non-neurological mechanisms 
of immune suppression have recently been described, with 
in vitro, in vivo, and ex vivo data revealing trauma results in 
the emergence into the circulation of suppressive immune cell 
subsets and damage-associated molecular patterns (DAMPs), 
with exposure to the latter inducing tolerance in peripheral 
immune cells (115–119). In this section, we discuss these 
recent studies, relate their findings to TBI and propose that 
that the presence of suppressive immune cells and DAMPs in 
the circulation contributes to the immune suppression that is 
observed following TBI (Figure 1).
Myeloid-Derived Suppressor Cells as 
Mediators of In Vitro and In Vivo T-Cell 
Dysfunction Post-TBi
Myeloid-derived suppressor cells (MDSCs) are a heterogene-
ous population of cells consisting of myeloid progenitors and 
precursors of granulocytes, macrophages, and dendritic cells. 
First described in the field of cancer research and characterized 
since in a number of pathological conditions such as sepsis, 
autoimmunity, and trauma, MDSCs are potent suppressors 
of T-cell function (120, 121). Via the production of ROS and 
reactive nitrogen species, expression of arginase 1, and secretion 
of immunosuppressive cytokines, MDSCs inhibit T-cell prolif-
eration, promote T-cell apoptosis, block translation of the T-cell 
CD3ζ chain, and mediate expansion of CD4+CD25+FoxP3+ 
regulatory T cells (120, 121).
In murine models of trauma (122) and chronic physiological 
stress (123), endogenous GCs and catecholamines have recently 
been shown to promote the expansion and accumulation of 
MDSCs. Thus, if we assume that akin to other forms of traumatic 
injury (115, 116), the initial act of brain injury is sufficient to 
cause MDSC release from the bone marrow then the increased 
serum levels of GCs and catecholamines found in TBI patients is 
an environment that favors MDSC proliferation and expansion. 
Consequently, it is not inconceivable that the presence of MDSCs 
in circulation could be one mechanism underlying the profound 
in vivo and in vitro T-cell suppression that occurs following TBI 
(25–28, 61). In fact, this scenario may have already been described. 
In a study published prior to the discovery of MDSCs, Quattrocchi 
et al. (29) found that when cocultured with lymphocytes isolated 
from patients with severe TBI, peripheral blood mononuclear 
cells (PBMCs) from healthy controls exhibited significantly 
reduced LAK cytotoxicity, suggesting the presence of suppressor 
lymphocytes in TBI patients (29). Interestingly, when perform-
ing standard PBMC isolation protocols using Ficoll-Hypaque 
density gradient centrifugation, MDSCs due to their reduced 
buoyant density reside in the same layer as lymphocytes (124). 
Thus, it may be that the lymphocytes isolated from TBI patients 
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by Quattrocchi et al. (29) were contaminated with MDSCs and 
that it was these cells that were responsible for the reduction in 
T-cell cytotoxicity they reported.
Recently, MDSCs have been touted as a therapeutic target in 
the treatment of cancer with strategies aimed at either (1) deac-
tivating MDSCs, (2) blocking their development, or (3) driving 
FiGURe 1 | Proposed mechanisms underlying TBi-induced changes in peripheral innate and adaptive immunities. Applying the findings of studies 
performed on patients with general trauma (111, 113–115, 118, 122, 127) and CNS injury (131) to the hospitalized TBI patient, we propose three novel mechanisms 
contribute in part to the peripheral immune suppression that is observed post-TBI. Mechanism 1: secondary complications arising from TBI such as raised 
intracranial pressure (ICP) and cerebral ischemia result in elevated serum levels of glucocorticoids (GCs) and catecholamines (CAs) through activation of the HPA 
axis and SNS, respectively. GCs and CAs drive the proliferation and accumulation of myeloid derived suppressor cells (MDSC) in the circulation that subsequently 
inhibit T-cell function via depletion of arginine from the local environment and the production of reactive oxygen species (ROS). Mechanism 2: TBI triggers emergency 
granulopoiesis, which results in the emergence into the circulation of immature granulocytes (IGs) and the generation of a heterogeneous pool of neutrophils that 
contains CD16BRIGHT CD16DIM-suppressive neutrophils. Through ROS generation, CD16BRIGHT CD16DIM neutrophils would suppress T-cell proliferation, while via direct 
cytotoxicity IGs would induce T-cell apoptosis and thus lymphocytopenia. Mechanism 3: neuronal cell death combined with disruption of the blood–brain barrier 
(BBB) would lead to the emergence into the circulation of both nuclear- and mitochondrial-derived damage-associated molecular patterns (DAMPs). The nuclear-
derived DAMP high mobility group box 1 (HMGB1) would promote the expansion of MDSCs, monocyte hyporesponsiveness, and lymphocytopenia, while the 
presence of mtDAMPs would induce a state of systemic immune cell tolerance. More specifically, as a consequence of exposure to N-formyl peptides, circulating 
neutrophils would exhibit reduced antimicrobial activity upon secondary stimulation, while mitochondrial DNA (mtDNA) would promote a state of endotoxin tolerance 
in circulating monocytes. The consequence of all three of these proposed mechanisms is profound suppression of the peripheral immune system, resulting in an 
increased susceptibility to infection and an increased risk of poor outcome.
their differentiation into mature cells all currently under clinical 
investigation (125). If through future research, MDSCs are found 
to play a role in TBI-induced immune dysfunction then similar 
approaches may be worth considering as a potential therapeutic 
avenue for the treatment of nosocomial infections in the hospital-
ized TBI patient.
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Suppressive CD16BRiGHT CD62LDiM 
Neutrophils and CD16DiM immature 
Granulocytes as Potential Mediators of 
In Vivo T-Cell Dysfunction Post-TBi
Historically, neutrophils have been considered a relatively 
homogeneous cell population. However, in recent years it has 
become apparent that in times of severe systemic inflammation, 
distinct neutrophil subsets emerge into the circulation. Based 
on the differential surface expression of the Fc receptor CD16 
and the adhesion molecule L-selectin, three distinct neutrophil 
subsets, defined as CD16DIM CD62LBRIGHT, CD16BRIGHT CD62LDIM, 
or CD16BRIGHT CD62LBRIGHT have been identified in severely 
injured patients (118). CD16BRIGHT CD62LDIM neutrophils have 
been shown in vitro to potently suppress T-cell proliferation via a 
Mac-1-dependent mechanism that involves the release of hydro-
gen peroxide into the immunological synapse that forms between 
CD16BRIGHT CD62LDIM neutrophils and T cells (118). Importantly, 
CD16BRIGHT CD62LDIM neutrophils are a subset of mature neutro-
phils, thereby distinguishing them from the above-mentioned 
immature MDSCs who also suppress T-cell function (118). 
Currently, it is unknown as to whether suppressive CD16BRIGHT 
CD62LDIM neutrophils form part of the expanded peripheral neu-
trophil pool that is observed following TBI, although one study in 
patients with severe TBI recently reported a significant reduction 
in both CD62L surface density and the percentage of CD62L+ 
neutrophils, suggesting that suppressive neutrophils may be 
released into the circulation post-TBI (34). Hypothetically, their 
presence may be one explanation for the suppressed DTH skin 
test responses elicited by patients with severe TBI (25, 28, 61).
CD16DIM neutrophils possess a “young” banded morphology, 
suggesting that these cells are immature granulocytic precursors 
(118). In a recent study of patients with septic shock, a subset of 
immature granulocytes (IGs) phenotypically defined as CD16DIM 
14− 24+ were described and shown in  vitro to elicit potent 
cytotoxicity against CD3+ lymphocytes (126). Interestingly, in 
these patients, a marked excess of CD16DIM IGs was found to 
be significantly associated with both CD3+ and CD4+ T-cell 
lymphopenia (126). On this note, a feature of the acute immune 
response to severe TBI is a significant increase in circulating IG 
numbers (33), whose elevation precedes the well-described CD3 
and CD4 T-cell lymphopenia that occurs in the hours and days 
following TBI (31, 40, 41). Thus, could the emergence of CD16DIM 
14− 24+ IGs into the circulation underlie the TBI-induced reduc-
tion in peripheral T cell numbers? Although intriguing, proposing 
CD16DIM 14− 24+ IG-induced T-cell apoptosis as a mechanism 
of T-cell lymphopenia post-TBI is premature given that it has 
yet to be established whether CD16DIM IGs cause T-cell death 
in vivo and the fact that no study to date has examined the sur-
face phenotype of IGs released in response to TBI to ascertain 
whether this CD16DIM 14− 24+ subset is present. That said should 
future work address these issues and prove in the setting of TBI 
that such a relationship exists then a potential therapeutic target 
could emerge. Accelerating the maturation of immature CD16DIM 
14− 24+ IGs through the systemic administration of agents 
capable of driving cellular differentiation could be one potential 
therapeutic avenue.
exposure to Damage-Associated 
Molecular Patterns – A Non-Neurological 
explanation for TBi-induced innate 
immune Dysfunction
Traumatic brain injury results in the emergence into the 
circulation (127) and cerebrospinal fluid (128) of mitochon-
drial DAMPs (mtDAMPs), a heterogeneous collection of 
mitochondrial-derived proteins and DNA that through binding 
to surface-expressed and endosomal residing pattern recognition 
receptors exhibit immune modulatory properties. In the case of 
isolated TBI, mtDAMPs originate from damaged neural tissue 
and through promoting the priming and activation of microglia 
and astrocytes are likely to orchestrate in part the inflammation-
induced secondary phase of brain injury (129). Diffusion across 
a disrupted blood–brain barrier is the most obvious mechanistic 
explanation for how neural-derived mtDAMPs gain entry into 
the circulation post-TBI (127). However, results of a recent 
study suggest that this may not be the only mechanism. In a 
seminal publication, Plog et al. have shown that inhibition of the 
glymphatic system, a highly organized system of CSF-interstitial 
fluid exchange, prevents the delivery of endogenously produced 
markers of brain injury into the bloodstream (130). To date, 
S100B, GFAP, and neuron-specific enolase have all been shown in 
a murine model of TBI to exit the CNS and enter the circulation 
through this system (130). As mtDAMPs would be released from 
damaged neural tissue alongside these molecules then it is not 
inconceivable to think that the mtDNA that has been detected in 
the circulation of human TBI patients (127) gained entry into the 
periphery via the glymphatic system.
In vitro, we have shown mtDAMPs to be potent activators of 
resting human neutrophils, triggering a number of robust func-
tional responses, which include ROS generation, degranulation, 
and IL-8 secretion (131), while in vivo, injection of mtDAMPs 
into mice results in among other things “priming” of circulating 
neutrophils (132). Therefore, given their presence in the circula-
tion of TBI patients (127), exposure to mtDAMPs may be one 
mechanism behind the increased basal ROS generation that has 
been reported in the immediate aftermath of TBI (35).
From results derived from a series of in  vivo, in  vitro, and 
ex vivo studies, it has recently been suggested that prior exposure 
to mtDAMPs, in particular N-formyl peptides, may suppress 
neutrophil antimicrobial function upon secondary stimulation 
(119). Li et  al. showed in  vitro that pretreatment with fMLP 
significantly reduced neutrophil chemotaxis to leukotriene 
B4, while ex vivo studies revealed neutrophils isolated from 
trauma patients, in whom circulating levels of mtDAMPs are 
increased (132), exhibited suppressed chemotaxis to a range of 
chemoattractants as well as impaired neutrophil extracellular 
trap generation following PMA stimulation (119). Based on 
these observations, the phrase “DAMP-induced tolerance” was 
coined, which proposes that mtDAMPs may tolerize circulat-
ing neutrophils to subsequent pathogenic danger signals (119). 
Relating these findings to TBI, neutrophils isolated from patients 
with severe TBI have been shown ex vivo to exhibit significantly 
reduced ROS generation and phagocytosis when challenged with 
E. coli (36). Thus, could it be that by initiating neutrophil activation 
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in  vivo, circulating mtDAMPs are responsible in part for the 
reduced anti-microbial activity of neutrophils post-TBI and hence 
the increased susceptibility of these patients to nosocomial infec-
tion? To answer this question, a greater understanding of the type 
and amount of mtDAMPs released following TBI and the effect 
that prior exposure to mtDAMPs has on other antimicrobial 
functions of neutrophils besides chemotaxis and NET generation 
is needed. Interestingly, in the field of burns research, a recent 
study that enrolled patients with combined inhalation and burn 
injury reported that elevated levels of two DAMPs, namely hya-
luronic acid and double-stranded DNA, in bronchial washings 
were significantly associated with bacterial respiratory infection 
during the first 14 days after injury (133). Although neutrophil 
function was not investigated directly in the study, alterations 
in neutrophil biology were proposed as one explanation for the 
relationship between DAMPs and the increased susceptibility 
of burns’ patients to infection, with the authors suggesting that 
DAMPs may trigger polarization of neutrophils toward an IL-10+ 
IL-12− anti-inflammatory phenotype (133).
Defined as “the severely reduced capacity of a cell to respond to 
LPS during a second exposure to this stimulus” (134), endotoxin 
tolerance (ET) describes a transient refractory state, which in 
monocytes is characterized in part by reduced proinflammatory 
cytokine production and high surface expression of CD163, two 
features reminiscent of anti-inflammatory “M2” macrophages 
(135). Interestingly, mtDAMPs, in particular mtDNA, are potent 
inducers of ET in human monocytes (136). Fernández-Ruiz et al. 
(136) found that when challenged with LPS, monocytes pretreated 
with mtDNA exhibited among other things significantly reduced 
proinflammatory cytokine production and enhanced IL-10 secre-
tion, leading to the suggestion that DAMPs may play a pivotal 
role in the refractory state of monocytes in “sterile” pathologies 
(136). On this note, significantly greater numbers of circulating 
anti-inflammatory “M2” monocytes and increased intracellular 
expression of IL-10 in monocytes has been reported post-TBI (30, 
37), suggesting the presence of an immune-suppressive mono-
cyte pool. If, as reported in other patient cohorts (136), future 
studies were to show that the elevation in circulating mtDNA that 
occurs following TBI (127) is associated with the development 
of monocyte ET and an increased incidence of infection, then 
an early assessment of the functional response of circulating 
monocytes to LPS may identify TBI patients at risk of develop-
ing nosocomial infection. In support of this concept, Pena et al. 
recently demonstrated in a cohort of critically ill patients that at 
the time of clinical presentation, a unique ET gene expression 
profile in PBMCs could be used to predict the development of 
sepsis and organ failure (134).
As described earlier, autoantibodies specific for CNS-residing 
proteins have been detected in the serum of patients that have 
suffered either mild (62) or severe (63) TBI. Given that damage 
to neural tissue results in the emergence into the circulation of 
mtDAMPs, could these components lead to immune dysregula-
tion in the TBI patient by triggering an autoimmune response? 
Currently, no study to our knowledge has investigated this pos-
sibility. However, autoantibodies directed against mitochondria 
and mtDNA have been detected in patients with inflammatory 
disease (137) and neurodevelopmental disorders (138), and 
anti-mtDNA antibodies have been shown in vitro to drive a robust 
proinflammatory response from circulating immune cells (137). 
If replicated in the setting of TBI, one could envisage how after 
crossing the “leaky” BBB, autoantibodies against CNS-residing 
mtDAMPs could trigger an inflammatory reaction from local 
microglia and astrocytes that contributes to the onset of second-
ary brain injury.
In animal models of experimental brain ischemia, the nuclear-
derived DAMP high mobility group box 1 (HMGB1) has been 
linked to the development of CNS injury-induced immune sup-
pression (139). Released into the extracellular environment as a 
consequence of cellular necrosis or active secretion by immune 
cells, HMGB1 was shown in vivo to promote the expansion of 
MDSCs as well as partially mediate stroke-induced lymphocyto-
penia and monocyte hyporesponsiveness (139). Given that akin 
to stroke, TBI results in elevated plasma levels of HMGB-1 (140), 
could the presence of this DAMP in the circulation underlie not only 
the well-established features of TBI-induced immune suppression 
(e.g., lymphocytopenia and immune exhaustion) but also those 
immune changes we have proposed may occur following TBI (e.g., 
emergence of MDSCs)? A future study that measures immune 
function alongside HMGB-1 levels would address this question, 
and if a role for HMGB-1 in TBI-induced immune suppression 
was found then a therapeutic target for the prevention of immune 
dysfunction post-TBI could emerge.
TBi AND PeRiPHeRAL iMMUNe 
SUPPReSSiON – UNANSweReD 
QUeSTiONS AND FUTURe 
OPPORTUNiTieS
Despite the recent surge of interest in TBI and its impact on 
peripheral immunity (31–38, 141–143), our understanding of 
this subject remains equivocal at best. Thus, in this section, in an 
effort to move this field of research forward, a series of questions 
are posed, the answers to which we feel would provide much 
needed information not only on the mechanisms underlying 
TBI-induced changes in immunity but whether therapeutic 
intervention aimed at manipulating peripheral immune function 
has potential as a future treatment option for the hospitalized TBI 
patient.
Q1. what are the Acute and Long-Term 
effects of TBi on Peripheral immune 
Function?
A question that has not been properly addressed in the field of 
TBI and trauma research in general is how quickly following a 
traumatic insult do changes in peripheral immunity occur? In the 
TBI studies described in this review, collection of the first blood 
sample postinjury has ranged from ≤3 to 72 h, a broad time-frame 
that may explain in part some of the conflicting observations that 
have been reported to date in respect of the impact of TBI on 
peripheral immunity. Without a complete understanding of the 
immediate immune response to TBI, it is likely that information 
that may be useful for the clinician when deciding upon treatment 
protocols for the injured patient is being missed. For instance, 
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Rovlias et al. demonstrated the benefit of early blood sampling 
by showing that white blood cell counts in admission blood sam-
ples (within 2 h of injury) could independently predict patient 
outcome at 6 months (144). In another study, Pagowska-Klimek 
et  al. measured neutrophil function in blood samples taken 
0.5–2  h (mean 1  h) following isolated head injury in children 
and reported significantly reduced ROS generation following 
PMA and fMLP stimulation (145), demonstrating the immedi-
ate impact that TBI can have on peripheral immunity. However, 
whether this early impairment in neutrophil function resulted 
in an increased incidence of infection or poor outcome was not 
determined. Performing similar studies in adult patients that not 
only analyze the very early functional immune response to TBI 
but collect detailed information on a series of clinical outcomes, 
such as infection, development of sepsis, and mortality, would 
generate novel data that could have potential clinical benefit.
In addition to a lack of understanding of the immediate 
immune response to TBI, very little is known in respect of the 
long-term impact that TBI has on immune function. In the 
field of burns research, it has been reported that it takes a total 
of 3.5  months following thermal injury for the oxidative burst 
capacity of circulating neutrophils to return to a level that 
resembles that of healthy controls (146). In adult TBI patients, a 
significant reduction in the phagocytic activity of circulating neu-
trophils has been reported up to 2 weeks postinjury (35), while 
the immediate suppression in the frequency and absolute number 
of CD3−56+ NK cells that accompanies TBI is maintained up to 
21 days postinjury (38). In rodent models of TBI, significantly 
reduced numbers of thymocytes, monocytes, and tissue mac-
rophages as well as a decline in thymic mass has been recorded 
at 60 days postinjury (37). As these results suggest that TBI may 
have long-lasting detrimental effects upon the immune system, it 
would be interesting for future studies to assess, via a longitudinal 
approach, the extent to which TBI impacts upon the long-term 
functioning of the immune system especially since mortality as a 
result of infection has been reported in patients with severe TBI 
as late as 3 months postinjury (147).
Q2. Could a Heterogeneous Pool of 
Circulating Neutrophils explain the 
Alterations in Neutrophil Function 
Observed Post-TBi?
Neutrophilia is a well-described feature of the immune response 
to TBI (34, 35, 39), yet no study to date has examined the com-
position of this enlarged neutrophil pool. Although unknown in 
respect to TBI, severe traumatic injury results in a heterogeneous 
neutrophil pool that broadly consists of two distinct subsets, 
namely CD16BRIGHT and CD16DIM (118). Compared to their 
CD16BRIGHT counterparts, CD16DIM neutrophils exhibit sig-
nificantly reduced ROS generation, phagocytosis, and bacterial 
killing (117, 148). Given that these three neutrophil functions 
are significantly impaired following severe TBI (35, 36, 40, 
149), could it be that akin to other forms of traumatic injury, TBI 
results in a heterogeneous neutrophil pool? Since all studies that 
have examined the impact of TBI on neutrophil biology to date 
have considered the circulating neutrophil pool to be a single 
homogenous population, the answer to this question is currently 
unknown. By addressing this issue, a greater understanding of 
the mechanisms that underlie TBI-induced immune suppression 
would be gained and potential therapeutic targets identified.
Q3. Can Peripheral immune Suppression 
and/or mtDAMPs Serve as a Biomarkers 
of Outcome in the Traumatically Brain 
injured Patient?
Recently, a number of studies have demonstrated that changes 
in peripheral immunity are associated with and/or can predict 
outcome in TBI patients. Focusing primarily upon the inflamma-
tory response to TBI, studies have shown increased levels of IL-6, 
IL-8, and IL-10 are associated with fatal outcome following severe 
TBI, with elevated IL-10 levels being associated with hospital 
mortality independent of patient age, GCS score, pupil reactivity 
at admission, and associated trauma (141, 142). In addition to 
mortality, raised serum IL-6 levels within 17 h of injury have been 
found to be a good prognostic marker for the development of 
raised intracranial pressure following isolated TBI (150), while 
an elevated IL-6:IL-10 ratio was associated with an increased risk 
of an unfavorable GOS score at 6 months postsevere TBI (143). 
Besides inflammatory cytokines, leukocytosis has been shown to 
be of prognostic significance in TBI patients. High white blood 
cell counts within the first day following injury have been found 
to be associated with a longer length of hospital stay (151), mor-
tality (33), and unfavorable neurological outcome at 6 months, 
with this latter association independent of GCS score, pupillary 
reaction, age, and intracranial diagnosis (144, 151).
Whether the peripheral immune suppression that occurs 
post-TBI can be used to predict the development of infection 
is currently unknown, although this approach has proven to be 
successful in other cohorts of patients with CNS injury. In stroke 
patients, in whom infections are associated with higher mortal-
ity rates and poor functional outcome (152), several features of 
stroke-induced immune depression have been shown to be associ-
ated with and/or independently predict the development of noso-
comial infection. These include: (1) reduced monocytic HLA-DR 
expression and low CD4+ T-cell counts (153, 154), (2) reduced 
ex vivo TNF-α release by monocytes (155), and (3) elevated plasma 
IL-10 levels (156). In addition, it has recently been postulated that 
a rise in the frequency of circulating CD64+ neutrophils 1 week 
after stroke may serve as a marker by which to identify an inflam-
matory response developing as a consequence of infection (157). 
In the context of TBI-induced immune suppression, no study to 
our knowledge has examined whether alterations in neutrophil 
surface phenotype can predict the development of infection, a 
reflection of the paucity of data in this area of research. There have 
however been reports of reduced ROS production by neutrophils 
isolated from infected TBI patients compared to non-infected 
patients (36). That said this relationship was not predictive and 
the potential impact of confounders were not considered. This 
lack of comprehensive statistical analysis is also a limitation of a 
study where infected patients with severe TBI were found to have 
significantly lower circulating frequencies of CD3+56−, CD3+4+ 
and CD3+8+ T cells as well as CD3−56+ NK cells at the time of 
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infection occurrence when compared to non-infected patients 
(31). Thus, although associated with nosocomial infection, it 
remains to be established whether TBI-induced immune sup-
pression can be used to independently predict the development of 
infection. Given the range of adverse outcomes that are associated 
with infection in TBI patients (11, 14, 15, 17, 20, 21) and the ben-
efit that early detection may have on patient health, addressing 
this issue should form a significant part of future TBI research.
Aside from immune function, could the presence of mtDAMPs 
serve as a biomarker of injury severity or patient outcome post-TBI? 
In other fields of trauma research, plasma levels of mtDNA have 
been found to (i) positively correlate with injury severity score 
(ISS) (158–160), (ii) be significantly higher in admission samples 
from non-survivors compared to survivors (158, 161, 162), and 
(iii) be predictive of and/or associated with the development of 
a systemic inflammatory response or multiple organ failure (160, 
161). However, whether mtDAMPs are suitable diagnostic or 
prognostic markers in TBI is currently unclear. In the only study 
to our knowledge that has measured circulating mtDAMPs in 
human TBI patients, Wang et al. found that although significantly 
increased when compared to healthy controls, plasma mtDNA 
levels on admission did not correlate with either GCS score or 
ISS (127). Similarly, no association was observed between mtDNA 
levels in admission CSF samples and GCS score in a cohort of 
pediatric TBI patients (128). However, CSF mtDNA concentra-
tion was found to predict with a reasonable degree of specificity 
(84.2%) patient outcome at 6 months (128). More recently, in a 
porcine model of focal and diffuse TBI, Kilbaugh et al. reported a 
significant increase in relative mtDNA copy numbers in peripheral 
blood at 6 and 25 h postinjury (163). Interestingly, this increase 
was shown to correlate with a reduction in cerebral mitochondrial 
respiration, leading to the proposal that enumeration of relative 
mtDNA copy numbers in peripheral blood could represent a novel 
signature of cerebral mitochondrial dysfunction post-TBI (163).
Q4. is Reversing TBi-induced immune 
Suppression a Potential Therapeutic 
Strategy for the Treatment of Nosocomial 
infections in the Hospitalized TBi Patient?
The majority of studies that have investigated whether the immune 
system is a potential therapeutic target for the treatment of TBI 
have focused upon developing immune suppressive strategies as 
a means of treating and/or preventing the secondary injury phase 
of TBI. To date, these strategies have included (1) neutrophil 
depletion, which reduced edema formation and attenuated brain 
tissue loss (164), (2) ghrelin therapy, which reduced peripheral 
monocyte and neutrophil recruitment to the site of brain injury 
(165), and (3) blocking leukotriene synthesis, which resulted in 
an attenuation in brain swelling and reduced blood–brain barrier 
permeability (166). Given the interest in preventing secondary 
injury following TBI, very little is known, particularly in humans, 
as to whether counteracting TBI-induced immune suppression 
may be a useful approach for the prevention of infection in the 
hospitalized TBI patient. While it may seem counterintuitive to 
enhance immune activity to eradicate infection given that immune 
hyperactivity is central to the pathophysiology of secondary brain 
injury, it has been suggested that such approaches would only 
commence when any secondary injuries are controllable (147).
In a randomized, placebo-controlled, double-blind, multicen-
tre phase II study, Heard et al. prospectively investigated whether 
the use of prophylactic recombinant human granulocyte colony-
stimulating factor (G-CSF) could reduce the frequency of noso-
comial infections in patients with acute TBI (167). They found 
that while G-CSF treatment had no impact on the frequency of 
pneumonia or urinary tract infections, it was associated with a sig-
nificant reduction in the frequency of primary bacteremias (167). 
However, the study found no beneficial effect for G-CSF therapy 
on patient mortality or length of hospital stay (167). Following 
on from this work, Ishikawa et  al. investigated whether G-CSF 
treatment could reduce the incidence of life-threatening infections 
in eight patients with severe TBI that were undergoing combined 
therapy with barbiturates and mild hypothermia, a treatment 
protocol known to increase infection risk (147). The group found 
that compared to patients who did not receive G-CSF therapy, 
prevalence rates of pneumonia and meningitis were significantly 
lower in G-CSF treated patients (147). Moreover, compared to 
baseline values, G-CSF treatment resulted in a significant increase 
in circulating neutrophil numbers and antimicrobial function with 
respect to phagocytic and bactericidal activities, suggesting that 
an enhancement in immune function had protected the patients 
from contracting nosocomial infection (147). Given the potential 
clinical significance of this study, it is surprising that in the 16 years 
since its publication no group has taken this research forward, 
especially since during this time period, immunomodulation in 
other forms of traumatic injury has proven successful in protecting 
against the development of post-traumatic infection (168, 169). 
Thus, it remains to be established whether therapies aimed at 
restoring immune function would be of benefit to the hospitalized 
TBI patient in terms of reducing their susceptibility to infection.
CONCLUSiON
In this review article, we have proposed that the emergence into 
the circulation of hematopoietic cells with suppressive activity 
underlies in part the immune suppression that is observed fol-
lowing TBI. If future studies prove this hypothesis to be correct 
then could these cells be manipulated for the clinical benefit of 
the hospitalized TBI patient in respect of reducing infection risk? 
Interestingly, therapeutic interventions are being trialed in other 
cohorts of patients to address similar questions. For instance, a 
series of strategies aimed at manipulating the function of MDSCs 
are currently under clinical investigation as a novel treatment 
for cancer (125), while in the field of sepsis research, groups are 
examining whether it is possible to remove individual neutrophil 
subsets from the circulation. On this note, ex vivo filtration of 
blood from patients with septic shock has been found to preferen-
tially remove neutrophils with an activated phenotype (CD11bhigh, 
CD64high, and CXCR1/2low) (170). If, as we have proposed, suppres-
sive CD16BRIGHT CD62LDIM neutrophils emerge into the circulation 
following TBI and are involved in TBI-induced immune suppres-
sion then it would be of interest to determine whether a similar 
filtration approach to remove this specific neutrophil subset could 
be beneficial in terms of reducing infection risk in TBI patients.
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